NEW YORK (GenomeWeb) – Response Genetics' first quarter revenues dropped 30 percent year over year despite an increase in its ResponseDX revenues, the company said today.

For the three months ended March 31, total revenues fell to $3.9 million from $5.6 million a year ago. ResponseDX revenues were up about 4 percent year over year to $3.3 million, but revenues from its pharmaceutical clients shrank by $1.9 million, Response said, due to the timing of services performed for the firm's largest pharma client.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.